The Washington Post reports that the Food and Drug Administration intends to add Guilliain-Barry syndrome (GBS), a rare autoimmune disease, to the list of warnings associated with vaccination with Johnson & Johnson. To date, about 100 cases of the disease have been reported among the 12.8 million people who have been vaccinated.
Today, Monday, the Centers for Disease Control and Prevention (CDC) released data on the number of cases of the disease. Most cases occurred about two weeks after the injection and were mainly related to men over 50 years of age. The CDC concluded that although these cases are very rare, they likely indicate a slightly increased risk of disease following J&J vaccination. Such an effect was not observed in those who were vaccinated with Moderna and Pfizer preparations.
Guillain-Barre Syndrome (GBS) is A rare autoimmune condition that can cause inflammation of the nervous system as a result of a reaction by the immune system. Often manifested by a feeling of muscle weakness, pain in the extremities and back. Yeah. 5% of cases end in death, and every fifth patient suffers from movement problems after that. About 1-2 cases of the disease are diagnosed per 100,000 people annually. Persons.
Most often, the disease attacks people after a viral infection, but was previously linked to another swine flu vaccine in 1976. Possible cases of the disease have also occurred among people vaccinated with AstraZeneki, which uses the same J&J technology.
According to the Washington Post, the US Food and Drug Administration intends to add a warning about the increased risk of GBS associated with the Johnson & Johnson vaccine. However, it is also expected to note that the benefits of vaccination still far outweigh the risks.